Back to Journals » International Journal of Nanomedicine » Volume 6

Development and optimization of oil-filled lipid nanoparticles containing docetaxel conjugates designed to control the drug release rate in vitro and in vivo

Authors Feng, Wu H, Ma, Mumper R, Benhabbour SR

Published 21 October 2011 Volume 2011:6 Pages 2545—2556


Review by Single-blind

Peer reviewer comments 2

Lan Feng1, Huali Wu2, Ping Ma1, Russell J Mumper1,3, S Rahima Benhabbour1
1Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, 2Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, 3UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC, USA

Abstract: Three docetaxel (DX) lipid conjugates: 2’-lauroyl-docetaxel (C12-DX), 2’-stearoyl-docetaxel (C18-DX), and 2’-behenoyl-docetaxel (C22-DX) were synthesized to enhance drug loading, entrapment, and retention in liquid oil-filled lipid nanoparticles (NPs). The three conjugates showed ten-fold higher solubility in the liquid oil phase Miglyol 808 than DX. To further increase the drug entrapment efficiency in NPs, orthogonal design was performed. The optimized formulation was composed of Miglyol 808, Brij 78, and Vitamin E tocopheryl polyethylene glycol succinate (TPGS). The conjugates were successfully entrapped in the reduced-surfactant NPs with entrapment efficiencies of about 50%–60% as measured by gel permeation chromatography (GPC) at a final concentration of 0.5 mg/mL. All three conjugates showed 45% initial burst release in 100% mouse plasma. Whereas C12-DX showed another 40% release over the next 8 hours, C18-DX and C22-DX in NPs showed no additional release after the initial burst of drug. All conjugates showed significantly lower cytotoxicity than DX in human DU-145 prostate cancer cells. The half maximal inhibitory concentration values (IC50) of free conjugates and conjugate NPs were comparable except for C22-DX, which was nontoxic in the tested concentration range and showed only vehicle toxicity when entrapped in NPs. In vivo, the total area under the curve (AUC0-∞) values of all DX conjugate NPs were significantly greater than that of Taxotere, demonstrating prolonged retention of drug in the blood. The AUC0-∞ value of DX in Taxotere was 8.3-fold, 358.0-fold, and 454.5-fold lower than that of NP-formulated C12-DX, C18-DX, and C22-DX, respectively. The results of these studies strongly support the idea that the physical/chemical properties of DX conjugates may be fine-tuned to influence the affinity and retention of DX in oil-filled lipid NPs, which leads to very different pharmacokinetic profiles and blood exposure of an otherwise potent chemotherapeutic agent. These studies and methodologies may allow for improved and more potent nanoparticle-based formulations.

Keywords: docetaxel, nanoparticles, ester prodrug, sustained release

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Subtle cytotoxicity and genotoxicity differences in superparamagnetic iron oxide nanoparticles coated with various functional groups

Hong SC, Lee JH, Lee J, Kim HY, Park JY, Cho J, Lee J, Han DW

International Journal of Nanomedicine 2011, 6:3219-3231

Published Date: 7 December 2011

Electrostatic self-assembly of multilayer copolymeric membranes on the surface of porous tantalum implants for sustained release of doxorubicin

Guo X, Chen M, Feng W, Liang J, Zhao H, Tian L, Chao H, Zou X

International Journal of Nanomedicine 2011, 6:3057-3064

Published Date: 28 November 2011

Development and evaluation of pH-responsive single-walled carbon nanotube-doxorubicin complexes in cancer cells

Gu YJ, Cheng J, Jin J, Cheng SH, Wong WT

International Journal of Nanomedicine 2011, 6:2889-2898

Published Date: 17 November 2011

Translocation of PEGylated quantum dots across rat alveolar epithelial cell monolayers

Fazlollahi F, Sipos A, Kim YH, Hamm-Alvarez SF, Borok Z, Kim K-J, Crandall ED

International Journal of Nanomedicine 2011, 6:2849-2857

Published Date: 10 November 2011

Tat peptide-admixed elastic liposomal formulation of hirsutenone for the treatment of atopic dermatitis in Nc/Nga mice

Kang MJ, Eum JY, Jeong MS, Park SH, Moon KY, Kang MH, Kim MS, Choi SE, Lee MW, Lee DI, Bang H, Lee CS, Joo SS, Li K, Lee M-K, Seo SJ, Choi YW

International Journal of Nanomedicine 2011, 6:2459-2467

Published Date: 20 October 2011

Doxorubicin-loaded PEG-PCL copolymer micelles enhance cytotoxicity and intracellular accumulation of doxorubicin in adriamycin-resistant tumor cells

Diao YY, Li HY, Fu YH, Han M, Hu YL, Jiang HL, Tsutsumi Y, Wei QC, Chen DW, Gao JQ

International Journal of Nanomedicine 2011, 6:1955-1962

Published Date: 12 September 2011

Evaluation of injectable silica-embedded nanohydroxyapatite bone substitute in a rat tibia defect model

Xu W, Ganz C, Weber U, Adam M, Holzhüter G, Wolter D, Frerich B, Vollmar B, Gerber T

International Journal of Nanomedicine 2011, 6:1543-1552

Published Date: 2 August 2011

Nanotoxicology and nanoparticle safety in biomedical designs

Ai J, Biazar E, Jafarpour M, Montazeri M, Majdi A, Aminifard S, Zafari M, Akbari HR, Rad HG

International Journal of Nanomedicine 2011, 6:1117-1127

Published Date: 31 May 2011

Time-dependent effect in green synthesis of silver nanoparticles

Darroudi M, Ahmad MB, Zamiri R, Zak A, Abdullah AH, Ibrahim NA

International Journal of Nanomedicine 2011, 6:677-681

Published Date: 5 April 2011